Inspirata

History

2022: Fujifilm bought IT solutions business from Inspirata to detect pathologies

On December 20, 2022, Fujifilm announced an agreement with Inspirata to purchase IT business assets to identify pathologies.

Upon completion of the agreement, Fujifilm acquires Inspirata's Dynamyx digital pathology technology. In addition, it accepts employees and customers of the company. Fujifilm expects to complete the deal in early 2023. The terms of the agreement were not disclosed.

Inspirata FDA ON received approval for Dynamyx digital pathology in March 2022. Dynamyx allows you to use whole slide images (WSIs) for primary diagnostics instead of traditional glass slides. The software includes an intuitive user interface with many annotation tools. It also has a universal viewer and customisable third-party apps AI that will be available to pathologists as needed.

Fujifilm Office Building

Fujifilm said in a press release that the acquisition expands Synapse's offering for corporate image processing. It allows you to integrate pathological images into the organization's electronic medical record system. According to the company's management, this can help optimize the process of providing care to cancer patients and groups of doctors.

Acquiring a digital pathology business from Inspirata enables Fujifilm to become an even stronger healthcare partner - bridging the technological gap between pathology, radiology and oncology to promote a more collaborative approach to healthcare delivery across the enterprise, said President and CEO Teiichi Goto.

The acquisition builds on an established partnership between Fujifilm and Inspirata. In 2020, the companies entered into a commercial partnership to use the digital pathology platform. The partnership began with exclusivity in, Great Britain,, Italy,,, and Spain Portugal. Belgium Netherlands Luxembourg

Fujifilm said the portfolio replenishment would allow the company to offer "one of the most comprehensive corporate image portfolios on the market." It also creates opportunities to support pharmaceutical and contract research organizations in managing toxicity testing data.^[1]

Notes